MCID: DFF036
MIFTS: 49

Differentiated Thyroid Carcinoma

Categories: Endocrine diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Differentiated Thyroid Carcinoma

MalaCards integrated aliases for Differentiated Thyroid Carcinoma:

Name: Differentiated Thyroid Carcinoma 59
Papillary or Follicular Thyroid Carcinoma 59
Differentiated Thyroid Gland Carcinoma 73
Well-Differentiated Thyroid Carcinoma 59

Characteristics:

Orphanet epidemiological data:

59
differentiated thyroid carcinoma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Worldwide),1-9/100000 (Europe); Age of onset: Adult;

Classifications:

Orphanet: 59  
Rare endocrine diseases


External Ids:

Orphanet 59 ORPHA146
ICD10 via Orphanet 34 C73
UMLS via Orphanet 74 C0238463
UMLS 73 C1337013

Summaries for Differentiated Thyroid Carcinoma

MalaCards based summary : Differentiated Thyroid Carcinoma, also known as papillary or follicular thyroid carcinoma, is related to thyroid cancer, nonmedullary, 2 and thyroid cancer. An important gene associated with Differentiated Thyroid Carcinoma is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Sorafenib and Iodine have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and bone, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Differentiated Thyroid Carcinoma

Diseases related to Differentiated Thyroid Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Related Disease Score Top Affiliating Genes
1 thyroid cancer, nonmedullary, 2 30.3 BRAF NRAS PAX8 PPARG
2 thyroid cancer 29.8 BRAF CCDC6 NCOA4 NRAS NTRK1 PAX8
3 thyroid cancer, nonmedullary, 1 28.9 BRAF CCDC6 GAS8-AS1 NCOA4 NTRK1 PAX8
4 familial papillary or follicular thyroid carcinoma 12.3
5 thyroiditis 10.9
6 erdheim-chester disease 10.8 BRAF NRAS
7 renal cell carcinoma, papillary, 1 10.7 BRAF NRAS PAX8
8 adult mesoblastic nephroma 10.7 ETV6 NTRK3
9 acral lentiginous melanoma 10.6 BRAF NRAS
10 papillary carcinoma 10.6 BRAF NCOA4 PAX8
11 pediatric fibrosarcoma 10.6 ETV6 NTRK3
12 cellular congenital mesoblastic nephroma 10.6 ETV6 NRAS NTRK3
13 congenital mesoblastic nephroma 10.6 ETV6 NRAS NTRK3
14 malignant struma ovarii 10.6 NCOA4 NRAS
15 peripheral nervous system neoplasm 10.5 ALK NRAS NTRK1
16 autonomic nervous system neoplasm 10.5 ALK NRAS NTRK1
17 melanoma, uveal 10.5 BRAF EIF1AX NRAS
18 brain cancer 10.4 ALK BRAF NRAS NTRK3
19 congenital fibrosarcoma 10.3 ETV6 NTRK3
20 adult fibrosarcoma 10.0 ETV6 NTRK3
21 aging 10.0
22 cervicitis 10.0
23 hypothyroidism 9.9
24 goiter 9.9
25 bronchiectasis 9.7
26 anaplastic thyroid cancer 9.7
27 laryngitis 9.7
28 diabetes mellitus, noninsulin-dependent 9.6
29 lymphoma 9.6
30 kidney disease 9.6
31 hashimoto thyroiditis 9.6
32 atrial fibrillation 9.6
33 adenoma 9.6
34 osteoporosis 9.6
35 thrombosis 9.6
36 peutz-jeghers syndrome 9.6
37 adenoid cystic carcinoma 9.6
38 hyperthyroidism 9.6
39 thrombophilia due to thrombin defect 9.6
40 thyroid lymphoma 9.6
41 hypoglycemia 9.6
42 graves' disease 9.6
43 polycystic kidney disease 9.6
44 intracranial hypertension, idiopathic 9.6
45 nodular goiter 9.6
46 endemic goiter 9.6
47 carcinoma showing thymus-like differentiation 9.6
48 lung cancer susceptibility 3 9.6
49 hyperparathyroidism 9.6
50 pulmonary sequestration 9.6

Graphical network of the top 20 diseases related to Differentiated Thyroid Carcinoma:



Diseases related to Differentiated Thyroid Carcinoma

Symptoms & Phenotypes for Differentiated Thyroid Carcinoma

GenomeRNAi Phenotypes related to Differentiated Thyroid Carcinoma according to GeneCards Suite gene sharing:

26 (show all 46)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 10.26 TPR
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-109 10.26 NTRK3
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-112 10.26 TRIM24
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 10.26 TPR NTRK1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-142 10.26 TRIM24
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.26 NTRK3
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.26 TRIM24
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-184 10.26 TRIM24 NTRK3
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-20 10.26 NTRK1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 10.26 TRIM24
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 10.26 TRIM24
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.26 NTRK1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 10.26 TRIM24 NTRK3
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.26 TRIM24 NTRK1 NTRK3 TPR
15 Decreased viability GR00055-A-2 10.11 BRAF
16 Decreased viability GR00221-A-1 10.11 PPARG ALK
17 Decreased viability GR00221-A-2 10.11 PPARG NTRK3
18 Decreased viability GR00221-A-3 10.11 PPARG
19 Decreased viability GR00221-A-4 10.11 NTRK3 PPARG TRIM27 ALK BRAF
20 Decreased viability GR00301-A 10.11 BRAF
21 Decreased viability GR00381-A-1 10.11 BRAF
22 Decreased viability GR00402-S-2 10.11 PPARG TRIM27 ALK BRAF NTRK3
23 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.07 BRAF
24 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.07 NCOA4
25 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.07 TRIM24
26 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.07 TRIM24
27 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.07 TRIM24
28 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.07 NCOA4
29 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.07 NCOA4
30 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.07 BRAF
31 Increased shRNA abundance (Z-score > 2) GR00366-A-159 10.07 NCOA4
32 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.07 NTRK1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.07 BRAF
34 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.07 BRAF
35 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.07 BRAF
36 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.07 BRAF
37 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.07 BRAF
38 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.07 BRAF
39 Increased shRNA abundance (Z-score > 2) GR00366-A-44 10.07 NCOA4
40 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.07 BRAF NCOA4 NTRK1 TRIM24
41 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.07 NTRK1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.07 NTRK1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.07 NCOA4
44 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.07 NTRK1 TRIM24
45 Decreased cell migration GR00055-A-1 9.72 ALK BRAF NTRK1 TRIM24 TRIM27
46 Reduced mammosphere formation GR00396-S 9.17 BRAF CCDC6 EIF1AX ETV6 NRAS PAX8

MGI Mouse Phenotypes related to Differentiated Thyroid Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 10.1 PAX8 PPARG TPR TRIM27 ALK BRAF
2 embryo MP:0005380 9.92 BRAF EIF1AX ETV6 LPAR4 NDUFA13 NRAS
3 neoplasm MP:0002006 9.7 ALK BRAF ETV6 NRAS PPARG TRIM24
4 no phenotypic analysis MP:0003012 9.5 ERC1 ETV6 NRAS NTRK1 NTRK3 PAX8
5 normal MP:0002873 9.23 ETV6 NRAS NTRK1 NTRK3 PAX8 PPARG

Drugs & Therapeutics for Differentiated Thyroid Carcinoma

Drugs for Differentiated Thyroid Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sorafenib Approved, Investigational Phase 3,Phase 2 284461-73-0 216239 406563
2
Iodine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7553-56-2 807
3
Salmon Calcitonin Approved, Investigational Phase 3,Phase 2 47931-85-1 16129616
4
Lenvatinib Approved, Investigational Phase 3,Phase 2,Phase 1 417716-92-8
5
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
6
Nicotinamide Approved, Investigational, Nutraceutical Phase 3,Phase 2 98-92-0 936
7
Niacin Approved, Investigational, Nutraceutical Phase 3,Phase 2 59-67-6 938
8
Calcitonin gene-related peptide Investigational Phase 3,Phase 2 83652-28-2
9 cadexomer iodine Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 calcitonin Phase 3,Phase 2
11 Micronutrients Phase 3,Phase 2,Phase 1,Not Applicable
12 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
13 Trace Elements Phase 3,Phase 2,Phase 1,Not Applicable
14 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
15 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
16 Vitamin B Complex Phase 3,Phase 2
17 Vitamins Phase 3,Phase 2,Not Applicable
18 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
19 Anti-Infective Agents, Local Phase 3,Phase 2,Phase 1,Not Applicable
20 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
21 Bone Density Conservation Agents Phase 3,Phase 2,Not Applicable
22 Nicotinic Acids Phase 3,Phase 2
23 Folate Nutraceutical Phase 3,Phase 2
24 Vitamin B9 Nutraceutical Phase 3,Phase 2
25 Vitamin B3 Nutraceutical Phase 3,Phase 2
26
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
27
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
28
Somatostatin Approved, Investigational Phase 2 38916-34-6, 51110-01-1 53481605
29
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
30
Metformin Approved Phase 2,Not Applicable 657-24-9 14219 4091
31
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
32
Valproic Acid Approved, Investigational Phase 2 99-66-1 3121
33
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
34
Dabrafenib Approved, Investigational Phase 2,Not Applicable 1195765-45-7 44462760 44516822
35
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
36
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
37
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
38
Gemcitabine Approved Phase 2 95058-81-4 60750
39
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
40
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
41
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
42
Mechlorethamine Approved, Investigational Phase 1, Phase 2 51-75-2 4033
43
Ifosfamide Approved Phase 1, Phase 2 3778-73-2 3690
44
Salicylic acid Approved, Investigational, Vet_approved Phase 2 69-72-7 338
45
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
46
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
47
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
48
Everolimus Approved Phase 2 159351-69-6 6442177
49
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
50
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337

Interventional clinical trials:

(show top 50) (show all 125)
# Name Status NCT ID Phase Drugs
1 A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer Recruiting NCT03573960 Phase 4 Lenvatinib
2 Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy Recruiting NCT02946918 Phase 4 Levothyroxine
3 Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients Unknown status NCT00435851 Phase 3 Thyrogen, thyroid hormone withdrawal, iode 131
4 Multicenter Study Differentiated Thyroid Carcinoma Completed NCT00144079 Phase 3
5 Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer Completed NCT00984282 Phase 3 Sorafenib (Nexavar, BAY43-9006);Placebo
6 A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. Completed NCT00295763 Phase 3 Thyrogen (thyrotropin alfa for injection)
7 The Usefulness of Staining Lymph Nodes During Operations for Cancer Thyroid in Detecting the Nodes That Have Cancer Completed NCT00794053 Phase 3
8 Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration Completed NCT00196729 Phase 3 Thyrogen + Radioiodine (131I)
9 Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032) Recruiting NCT02586337 Phase 2, Phase 3 Anlotinib;Placebo
10 Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer Recruiting NCT03048877 Phase 3 Apatinib Oral Tablet;Placebo Oral Tablet
11 A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China Recruiting NCT02966093 Phase 3 Lenvatinib;Placebo
12 Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients? Recruiting NCT01837745 Phase 3 rhTSH stimulation;I131
13 IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Recruiting NCT01398085 Phase 2, Phase 3
14 Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer Active, not recruiting NCT01843062 Phase 3 Selumetinib;Placebo;Radioactive Iodine Therapy
15 Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer Active, not recruiting NCT01876784 Phase 3 Vandetanib (SAR390530);Placebo
16 Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer Active, not recruiting NCT02418247 Phase 2, Phase 3 I131;I123
17 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC) Active, not recruiting NCT01321554 Phase 3 Lenvatinib;Placebo;Lenvatinib
18 Iodine I 131 With or Without Thyroid-Stimulating Hormone in Treating Patients Who Have Undergone Surgery for Thyroid Cancer Active, not recruiting NCT00415233 Phase 3
19 ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer Not yet recruiting NCT03570021 Phase 3
20 Study of Apatinib in Patients With Differentiated Thyroid Cancer Unknown status NCT02731352 Phase 2 Apatinib
21 Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer Unknown status NCT01229865 Phase 2 VB-111
22 Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer Unknown status NCT00098852 Phase 2 rosiglitazone maleate
23 Redifferentiation Therapy Using Alpha Lipoic Acid in Thyroid Cancer Unknown status NCT01396733 Phase 2 alpha-lipoic acids
24 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms Unknown status NCT01237457 Phase 2 177Lu-DOTATATE
25 Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer Unknown status NCT00181168 Phase 2 Recombinant thyrotropin
26 Effect of Carum Carvi on Thyroid Hormones and TSH Level Unknown status NCT01471288 Phase 1, Phase 2 Carum Cravi;Placebo
27 Comparison DW-MRI vs FDG PET/CT in the Detection of Early Recurrence of Cervical Well-differentiated Thyroid Carcinoma Completed NCT02515084 Phase 2
28 Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer Completed NCT00061906 Phase 2 celecoxib
29 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer Completed NCT00668811 Phase 2 SU011248, Sutent
30 Evaluating the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology Completed NCT00784303 Phase 2 E7080
31 Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer Completed NCT00124527 Phase 2 Irofulven + capecitabine
32 Phase II Study of IMRT With SIB as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer. Completed NCT00279721 Phase 2
33 Study of External Beam Radiotherapy to Thyroid Carcinoma Completed NCT01173289 Phase 2
34 Trial of LBH589 in Metastatic Thyroid Cancer Completed NCT01013597 Phase 2 LBH589
35 Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer Completed NCT00118248 Phase 2 tanespimycin
36 Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer Completed NCT00251316 Phase 2 Lithium Carbonate;Placebo
37 Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Completed NCT01811212 Phase 2 Cabozantinib S-malate
38 Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer Completed NCT00519896 Phase 2 sunitinib malate
39 Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma Completed NCT00887107 Phase 2 Sorafenib (nexavar)
40 CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer Completed NCT03002623 Phase 2 CUDC-907
41 Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer Completed NCT00654238 Phase 2 sorafenib
42 A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin Completed NCT01182285 Phase 2 Valproic Acid;Liothyronine Sodium
43 Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00104871 Phase 2 Bortezomib
44 A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer Completed NCT00121628 Phase 2 AMG 706
45 Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 Completed NCT00085293 Phase 2 Decitabine
46 Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma Recruiting NCT03167385 Phase 2 Apatinib Mesylate
47 PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma Recruiting NCT03387943 Phase 2 PLD;Cisplatin
48 A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting Recruiting NCT02041260 Phase 2 Cabozantinib
49 Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas Recruiting NCT03181100 Phase 2 Nab-paclitaxel - INDUCTION COHORT;Paclitaxel - INDUCTION COHORT;Vemurafenib - COHORT 1;Cobimetinib - COHORT 1;Atezolizumab - COHORT 1;Bevacizumab - COHORT 3;Nab-paclitaxel - COHORT 4;Paclitaxel - COHORT 4;Cobimetinib - COHORT 2;Atezolizumab - COHORT 2;Atezolizumab - COHORT 3;Atezolizumab - COHORT 4
50 Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer Recruiting NCT02870569 Phase 2 Donafenib 200mg;Donafenib 300mg

Search NIH Clinical Center for Differentiated Thyroid Carcinoma

Genetic Tests for Differentiated Thyroid Carcinoma

Anatomical Context for Differentiated Thyroid Carcinoma

MalaCards organs/tissues related to Differentiated Thyroid Carcinoma:

41
Thyroid, Lymph Node, Bone, Testes, Salivary Gland, Lung, Heart

Publications for Differentiated Thyroid Carcinoma

Articles related to Differentiated Thyroid Carcinoma:

(show top 50) (show all 489)
# Title Authors Year
1
The optimal TSH level necessary for successful radioiodine ablation of differentiated thyroid carcinoma, as well as the time to reach this level, is a work in progress. ( 29594409 )
2018
2
Clinicopathological and Survival Outcomes of Well-Differentiated Thyroid Carcinoma Undergoing Dedifferentiation: A Retrospective Study from FUSCC. ( 29951093 )
2018
3
Prognosis of Differentiated Thyroid Carcinoma with Initial Distant Metastasis: A Multicenter Study in Korea. ( 29947184 )
2018
4
Thyroidectomy Practice After Implementation of the 2015 American Thyroid Association Guidelines on Surgical Options for Patients With Well-Differentiated Thyroid Carcinoma. ( 29596551 )
2018
5
Use of radioiodine-131 scan to measure influence of surgical discipline, practice, and volume on residual thyroid tissue after total thyroidectomy for differentiated thyroid carcinoma. ( 29756327 )
2018
6
PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma. ( 29372535 )
2018
7
The effect of chewing-gum on dose rate of salivary gland in differentiated thyroid carcinoma patients treated with radioiodine. ( 29696945 )
2018
8
Prognostic significance of gross extrathyroidal extension invading only strap muscles in differentiated thyroid carcinoma. ( 29663333 )
2018
9
Impact on testicular function of a single ablative activity of 3.7 GBq radioactive iodine for differentiated thyroid carcinoma. ( 29912343 )
2018
10
Exploration of treatment de-escalation opportunities for differentiated thyroid carcinoma. ( 29398325 )
2018
11
Prevalence of adverse pathological features in 1 to 4a88cm low-risk differentiated thyroid carcinoma. ( 29417654 )
2018
12
Differentiated thyroid carcinoma presentation may be more aggressive in children and adolescents than in young adults. ( 29343289 )
2018
13
The Predictive Values of Lesion Size, F-18 FDG Avidity and I-131 Avidity for the Clinical Outcome of I-131 Treatment in Patients with Metastatic Differentiated Thyroid Carcinoma Only in the Lung. ( 29662562 )
2018
14
CRABP1, C1QL1 and LCN2 are biomarkers of differentiated thyroid carcinoma, and predict extrathyroidal extension. ( 29321030 )
2018
15
Less is More: The Impact of Multidisciplinary Thyroid Conference on the Treatment of Well-Differentiated Thyroid Carcinoma. ( 29058064 )
2018
16
Thyroglobulin &amp;quot;Nonsecretor&amp;quot; Metastatic Poorly Differentiated Thyroid Carcinoma with Noniodine Concentrating Disease and Aggressive Clinical Course: A Clinical Case Series. ( 29962718 )
2018
17
Psychosocial development in survivors of childhood differentiated thyroid carcinoma: a cross-sectional study. ( 29254931 )
2018
18
Seemingly Harmless Differentiated Thyroid Carcinoma Presenting as Bone Metastasis. ( 29967702 )
2018
19
A Follow-Up Strategy for Patients with an Excellent Response to Initial Therapy for Differentiated Thyroid Carcinoma: Less Is Better. ( 29179642 )
2018
20
Disease Burden and Outcome in Pediatric and Young Adults with Concurrent Graves Disease and Differentiated Thyroid Carcinoma. ( 29788090 )
2018
21
Differentiated thyroid carcinomas associated withA chronic thyroiditis: biological andA clinical properties. ( 29949530 )
2018
22
Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study. ( 29350109 )
2018
23
Young age is associated with increased rates of residual and recurrent paediatric differentiated thyroid carcinoma. ( 29672887 )
2018
24
Adipokines and inflammation markers and risk of differentiated thyroid carcinoma: The EPIC study. ( 29168186 )
2018
25
Clinical Value of<sup>99m</sup>Tc-3PRGD2 SPECT/CT in Differentiated Thyroid Carcinoma with Negative<sup>131</sup>I Whole-Body Scan and Elevated Thyroglobulin Level. ( 29323252 )
2018
26
Management of Solitary Intracranial Metastases of Differentiated Thyroid Carcinoma: 11 Pathologically Confirmed Cases and Systematic Literature Review. ( 29317366 )
2018
27
Insulin Resistance Associated With Differentiated Thyroid Carcinoma: Penalized Conditional Logistic Regression Analysis of a Matched Case-Control Study Data. ( 29696038 )
2018
28
Correction to: Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study, by Kim M, Kim TH, Shin DY, Lim DJ, Kim EY, Kim WB, Chung JH, Shong YK, Kim BH, and Kim WG on behalf of Korean Thyroid Cancer Study Group (KTCSG). Thyroid 2018;28(3)340-348. DOI: 10.1089/thy.2017.0356. ( 29749906 )
2018
29
Primary reconstructive method for tracheal defect from invasion by differentiated thyroid carcinoma. ( 28522300 )
2018
30
<sup>18</sup>F-FDG PET/CT and ultrasonogrpahy in differentiated thyroid carcinoma patients with elevated serum levels of antithyroglobulin antibody, negative Tg and whole body <sup>131</sup>I scan. ( 29550843 )
2018
31
Determining patient selection tool and response predictor for outpatient 30 mCi radioiodine ablation dose in non-metastatic differentiated thyroid carcinoma: a Japanese perspective. ( 29343651 )
2018
32
Pilocarpine effect on dose rate of salivary gland in differentiated thyroid carcinoma patients treated with radioiodine. ( 29517578 )
2018
33
Impact of Patient Age and Histological Type on Radioactive Iodine Avidity of Recurrent Lesions of Differentiated Thyroid Carcinoma. ( 29688947 )
2018
34
Improving care of patients with low-risk differentiated thyroid carcinoma. ( 29768626 )
2018
35
Effect of Lymph Node Metastasis on Change of Positive Thyroglobulin Antibody in Differentiated Thyroid Carcinoma after Initial Treatment. ( 28877833 )
2017
36
The Chinese herb Prunella vulgaris promotes apoptosis in human well-differentiated thyroid carcinoma cells via the B-cell lymphoma-2/Bcl-2-associated X protein/caspase-3 signaling pathway. ( 28808482 )
2017
37
Prognostic impact of vascular invasion in differentiated thyroid carcinoma: a systematic review and meta-analysis. ( 28566444 )
2017
38
Initial Size of Metastatic Lesions Is Best Prognostic Factor in Patients with Metastatic Differentiated Thyroid Carcinoma Confined to the Lung. ( 27750021 )
2017
39
Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma. ( 28423545 )
2017
40
Diastolic Dysfunction is Common in Survivors of Pediatric Differentiated Thyroid Carcinoma. ( 29132262 )
2017
41
Volumetric high-resolution computed tomography in evaluating pulmonary metastases from differentiated thyroid carcinoma: considerations for evolving the optimal diagnostic pathway. ( 28902716 )
2017
42
Vitamin D Deficiency Associated with Differentiated Thyroid Carcinoma: A Case- Control Study ( 29286613 )
2017
43
Pediatric differentiated thyroid carcinoma: The clinicopathological features and the coexistence of Hashimoto's thyroiditis. ( 29254871 )
2017
44
Cervical soft tissue recurrence of differentiated thyroid carcinoma after thyroidectomy indicates a poor prognosis. ( 28919092 )
2017
45
Long-term follow-up for differentiated thyroid carcinoma patients - a reconsideration. ( 28049373 )
2017
46
FNA diagnosis of poorly differentiated thyroid carcinoma. A review of the recent literature. ( 29094425 )
2017
47
Distant metastasis as the sole initial manifestation of well-differentiated thyroid carcinoma. ( 28382395 )
2017
48
A Functional Scoring System Based on Salivary Gland Scintigraphy for Evaluating Salivary Gland Dysfunction Secondary to<sup>131</sup>I therapy in Patients with Differentiated Thyroid Carcinoma. ( 28969240 )
2017
49
Patterns of failure in anaplastic and differentiated thyroid carcinoma treated with intensity-modulated radiotherapy. ( 28680291 )
2017
50
HBME-1 expression in differentiated thyroid carcinoma and its correlation with the ultrasonic manifestation of thyroid. ( 29151906 )
2017

Variations for Differentiated Thyroid Carcinoma

ClinVar genetic disease variations for Differentiated Thyroid Carcinoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
2 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh38 Chromosome 7, 140753336: 140753336
3 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 NCBI36 Chromosome 7, 140099605: 140099605

Expression for Differentiated Thyroid Carcinoma

Search GEO for disease gene expression data for Differentiated Thyroid Carcinoma.

Pathways for Differentiated Thyroid Carcinoma

GO Terms for Differentiated Thyroid Carcinoma

Biological processes related to Differentiated Thyroid Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 protein phosphorylation GO:0006468 9.91 ALK BRAF NTRK1 NTRK3 TRIM24
2 cell differentiation GO:0030154 9.91 ALK BRAF ETV6 NTRK1 NTRK3 PAX8
3 negative regulation of apoptotic process GO:0043066 9.89 ALK BRAF ERC1 NTRK1 NTRK3
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.78 ALK BRAF NTRK1 NTRK3
5 protein autophosphorylation GO:0046777 9.71 ALK NTRK1 NTRK3 TRIM24
6 positive regulation of kinase activity GO:0033674 9.63 ALK NTRK1 NTRK3
7 cellular response to retinoic acid GO:0071300 9.61 NDUFA13 NTRK3 PPARG
8 cellular response to nerve growth factor stimulus GO:1990090 9.43 BRAF NTRK1 NTRK3
9 mechanoreceptor differentiation GO:0042490 9.32 NTRK1 NTRK3
10 negative regulation of signal transduction GO:0009968 9.26 ALK BRAF NTRK1 NTRK3
11 neurotrophin signaling pathway GO:0038179 9.16 NTRK1 NTRK3
12 peptidyl-tyrosine phosphorylation GO:0018108 9.02 ALK NTRK1 NTRK3 TRIM24 TRIM27

Molecular functions related to Differentiated Thyroid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.83 ALK BRAF NTRK1 NTRK3 TRIM24
2 protein tyrosine kinase activity GO:0004713 9.67 ALK NTRK1 NTRK3 TRIM24
3 MAP kinase kinase kinase activity GO:0004709 9.46 ALK BRAF NTRK1 NTRK3
4 GPI-linked ephrin receptor activity GO:0005004 9.4 NTRK1 NTRK3
5 neurotrophin binding GO:0043121 9.32 NTRK1 NTRK3
6 neurotrophin receptor activity GO:0005030 9.26 NTRK1 NTRK3
7 mitogen-activated protein kinase kinase binding GO:0031434 9.26 ALK BRAF NTRK1 NTRK3
8 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.92 ALK NTRK1 NTRK3 TRIM27
9 protein binding GO:0005515 10.39 ALK BRAF CCDC6 EIF1AX ERC1 ETV6

Sources for Differentiated Thyroid Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....